Biocon secures USFDA approval for generic Liraglutide, entering the lucrative US obesity treatment market with gSaxenda.

Biocon Ltd is quoting at Rs 394.6, up 0.99% on the day as on 12:44 IST on the NSE. The stock is up 26.54% in last one year as compared to a 13.13% jump in NIFTY and a 13.84% jump in the Nifty Pharma.

Biocon’s Q3 revenue and EBITDA missed estimates, while profit rose sharply on a low base despite a ₹293 crore exceptional loss. The company also moved to fully integrate Biocon Biologics.

Biocon Limited on Thursday reported a 5.7-fold year-on-year (YoY) increase in consolidated net profit attributable to the ...

Mittal said the opportunity remains meaningful despite the broader GLP-1 market shifting toward newer therapies such as ...

Biocon Limited ( (IN:BIOCON)) just unveiled an update. Biocon Limited has increased its ownership in its unlisted material subsidiary, Biocon Biologics Limited (BBL), to around 94% of BBL’s fully ...

Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...

Nuvama has flagged four pharma stocks as top ‘Buy’ picks, citing strong US launches, biosimilars traction and margin expansion with potential upside of up to 27% over the next year.

Zee Business analysts have shared a number of short- and long-term calls, including Tata Motors PV, Infosys, Dr Reddy’s, RVNL ...

(RTTNews) - Viatris Inc. (VTRS) announced that it has entered into definitive agreements with Biocon Limited for the sale of its equity stake in Biocon Biologics Limited. Under the agreements, Biocon ...